STOCK TITAN
  1. Home
  2. News
  3. SENS

Senseonics Holdings Inc - SENS STOCK NEWS

Welcome to our dedicated news page for Senseonics Holdings (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Senseonics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Senseonics Holdings's position in the market.

News
Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS) plans to release its Q3 2023 financial results on November 9, 2023. The company is focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes. A conference call will be held to review the performance, which will be webcasted and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
earnings
-
News
Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes
Rhea-AI Summary
Ascensia Diabetes Care and Senseonics Holdings launch new advertising campaign for Eversense E3 CGM System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
News
Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study
Rhea-AI Summary
Senseonics completes ENHANCE Pivotal Clinical Study for Eversense CGM system, aims for FDA approval for 365-day system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
clinical trial
News
Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Summary
Senseonics Holdings, Inc. to present at Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences acquisition
-
News
Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital
Rhea-AI Summary
Senseonics Holdings, Inc. has entered into a $50 million loan facility with Hercules Capital, Inc. The company drew down $25 million upon closing. The loan facility provides increased financial flexibility and strengthens the balance sheet. Senseonics aims to fund its current operating plans and advance its product pipeline. The availability of additional tranches is subject to revenue and gross margin milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
none
-
News
Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Senseonics Holdings, Inc. reported Q2 2023 financial results, including revenue of $4.1 million. They also submitted an application to the FDA for an iCGM designation and received positive coverage from UnitedHealthcare. The company presented positive data at the ADA highlighting the longevity and accuracy of their Eversense System. Senseonics entered into exchange agreements to strengthen their balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
earnings
News
Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
Rhea-AI Summary
Senseonics Holdings, Inc. (NYSE-American: SENS) will release its second quarter 2023 financial results after market close on August 10, 2023. The company is focused on developing long-term implantable continuous glucose monitoring systems for people with diabetes. A conference call to review performance will be held at 4:30 p.m. (Eastern Time) on the same day, with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
-
News
Senseonics Announces Equity Grants To Employees Under Inducement Plan
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none
-
News
New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.75%
Tags
clinical trial
News
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
Rhea-AI Summary
Senseonics announces that UnitedHealthcare, the largest health insurance company in the US, will provide coverage for the Eversense E3 CGM System starting July 1, 2023, benefiting people with type 1 and insulin-requiring type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.17%
Tags
none
Stock SENS logo
Senseonics Holdings Inc

NYSE:SENS

SENS Rankings

#4117 Ranked by Market Cap
#4893 Ranked by Stock Gains
N/A Ranked by Dividends

SENS Stock Data

255.25M
507.34M
6.4%
12.45%
7.88%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Germantown

About SENS

senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm"​) system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.